Contemporary conceptions of etiology, pathogenesis, management and treatment of primary diffuse large b-cell central nervous system lymphoma
In this article we present the most up-to-date information about etiology, pathogenesis, diagnostic and treatment principles of primary central nervous system diffuse large B-cell lymphoma. We propose algorithm of diagnosis and treatment based on literature review and own experience. The main method...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/29 |
| _version_ | 1797855599466119168 |
|---|---|
| author | S. V. Voloshin Yu. A. Krivolapov A. V. Shmidt V. A. Shuvaev M. S. Fominykh K. M. Abdulkadyrov |
| author_facet | S. V. Voloshin Yu. A. Krivolapov A. V. Shmidt V. A. Shuvaev M. S. Fominykh K. M. Abdulkadyrov |
| author_sort | S. V. Voloshin |
| collection | DOAJ |
| description | In this article we present the most up-to-date information about etiology, pathogenesis, diagnostic and treatment principles of primary central nervous system diffuse large B-cell lymphoma. We propose algorithm of diagnosis and treatment based on literature review and own experience. The main methods for diagnosis verification are magneto-resonance tomography and stereotactic biopsy of mass with subsequent histological examination including immune staining. The common first-line therapy regimen is high-dose methotrexate therapy. However long-term prognosis still remains poor. Adverse prognostic factors for therapy response are age > 60 years, multifocal lesions, neurologic symptoms,previous treated disease. Considerable part of patient have contraindications or high-risk of adverse events for high-dose chemotherapy treatment. Anti-CD20 monoclonal antibody has no neurological toxicity with intravenous and intrathecal administrations. Combination therapy with reduced dose methotrexate and monoclonal antibody can be a reasonable treatment alternative for old and disable persons. The further survival improvement would be achieved by patient stratification and using of risk-adapted treatment algorithm. |
| first_indexed | 2024-04-09T20:25:22Z |
| format | Article |
| id | doaj.art-528b32a126784a05a7f0ce2b15515a34 |
| institution | Directory Open Access Journal |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| last_indexed | 2024-04-09T20:25:22Z |
| publishDate | 2014-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj.art-528b32a126784a05a7f0ce2b15515a342023-03-30T20:15:09ZrusABV-pressОнкогематология1818-83462413-40232014-07-018282110.17650/1818-8346-2013-8-2-8-2144Contemporary conceptions of etiology, pathogenesis, management and treatment of primary diffuse large b-cell central nervous system lymphomaS. V. Voloshin0Yu. A. Krivolapov1A. V. Shmidt2V. A. Shuvaev3M. S. Fominykh4K. M. Abdulkadyrov5Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico‑Biological AgencyI.I. Mechnikov North-Western State Medical University, Ministry of Health of RussiaRussian Research Institute of Hematology and Transfusiology, Russian Federal Medico‑Biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medico‑Biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medico‑Biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medico‑Biological AgencyIn this article we present the most up-to-date information about etiology, pathogenesis, diagnostic and treatment principles of primary central nervous system diffuse large B-cell lymphoma. We propose algorithm of diagnosis and treatment based on literature review and own experience. The main methods for diagnosis verification are magneto-resonance tomography and stereotactic biopsy of mass with subsequent histological examination including immune staining. The common first-line therapy regimen is high-dose methotrexate therapy. However long-term prognosis still remains poor. Adverse prognostic factors for therapy response are age > 60 years, multifocal lesions, neurologic symptoms,previous treated disease. Considerable part of patient have contraindications or high-risk of adverse events for high-dose chemotherapy treatment. Anti-CD20 monoclonal antibody has no neurological toxicity with intravenous and intrathecal administrations. Combination therapy with reduced dose methotrexate and monoclonal antibody can be a reasonable treatment alternative for old and disable persons. The further survival improvement would be achieved by patient stratification and using of risk-adapted treatment algorithm.https://oncohematology.abvpress.ru/ongm/article/view/29primary central nervous system diffuse large b-cell lymphomarisk-adapted treatmentrituximabmethotrexateintrathecal administration |
| spellingShingle | S. V. Voloshin Yu. A. Krivolapov A. V. Shmidt V. A. Shuvaev M. S. Fominykh K. M. Abdulkadyrov Contemporary conceptions of etiology, pathogenesis, management and treatment of primary diffuse large b-cell central nervous system lymphoma Онкогематология primary central nervous system diffuse large b-cell lymphoma risk-adapted treatment rituximab methotrexate intrathecal administration |
| title | Contemporary conceptions of etiology, pathogenesis, management and treatment of primary diffuse large b-cell central nervous system lymphoma |
| title_full | Contemporary conceptions of etiology, pathogenesis, management and treatment of primary diffuse large b-cell central nervous system lymphoma |
| title_fullStr | Contemporary conceptions of etiology, pathogenesis, management and treatment of primary diffuse large b-cell central nervous system lymphoma |
| title_full_unstemmed | Contemporary conceptions of etiology, pathogenesis, management and treatment of primary diffuse large b-cell central nervous system lymphoma |
| title_short | Contemporary conceptions of etiology, pathogenesis, management and treatment of primary diffuse large b-cell central nervous system lymphoma |
| title_sort | contemporary conceptions of etiology pathogenesis management and treatment of primary diffuse large b cell central nervous system lymphoma |
| topic | primary central nervous system diffuse large b-cell lymphoma risk-adapted treatment rituximab methotrexate intrathecal administration |
| url | https://oncohematology.abvpress.ru/ongm/article/view/29 |
| work_keys_str_mv | AT svvoloshin contemporaryconceptionsofetiologypathogenesismanagementandtreatmentofprimarydiffuselargebcellcentralnervoussystemlymphoma AT yuakrivolapov contemporaryconceptionsofetiologypathogenesismanagementandtreatmentofprimarydiffuselargebcellcentralnervoussystemlymphoma AT avshmidt contemporaryconceptionsofetiologypathogenesismanagementandtreatmentofprimarydiffuselargebcellcentralnervoussystemlymphoma AT vashuvaev contemporaryconceptionsofetiologypathogenesismanagementandtreatmentofprimarydiffuselargebcellcentralnervoussystemlymphoma AT msfominykh contemporaryconceptionsofetiologypathogenesismanagementandtreatmentofprimarydiffuselargebcellcentralnervoussystemlymphoma AT kmabdulkadyrov contemporaryconceptionsofetiologypathogenesismanagementandtreatmentofprimarydiffuselargebcellcentralnervoussystemlymphoma |